Overview
This project aims to integrate digital phenotyping and AI-driven iCBT into a comprehensive platform for MDD diagnosis and treatment in Taiwan. The study will explore dynamic, real-time behavioral and physiological markers to refine diagnostic classifications and optimize personalized therapeutic strategies.
Eligibility
Inclusion Criteria:
- (1) Aged 18-75 years
- Diagnosis of major depressive disorder disorder (Based on Diagnostic Statistical Manual 5)
- 21-item Hamilton Depression Scale (HAMD21)\>17
- No changes in current psychiatric treatment for depression (e.g., no treatment, antidepressant medication, psychotherapy, or non-invasive brain stimulation) within the past four weeks, and
- Full competency to understand the study details and provide written informed consent
Exclusion Criteria:
- Scores of 5 ( Markedly ill), 6,(Severely ill), and 7 (Among the most extremely ill) according to the Clinical Global Impression Scale-Severity (CGI-S)
- Psychotic disorders, bipolar affective disorder, a substance use disorders in the past 6 months, active suicidal or homicidal ideation (per assessment or HAMD\>3)
- Unstable or active medical illness.


